Meredith Brown-Tuttle, RAC Director APT Pharmaceuticals, Inc.

Slides:



Advertisements
Similar presentations
This presentation, including any supporting materials, is owned by Gartner, Inc. and/or its affiliates and is for the sole use of the intended Gartner.
Advertisements

Patients’ Perspective on HTA and Off-label use David Head MBA Chief Executive RP Fighting Blindness 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam.
Data Monitoring Models and Adaptive Designs: Some Regulatory Experiences Sue-Jane Wang, Ph.D. Associate Director for Adaptive Design and Pharmacogenomics,
CERT Program Manager: Training and Exercises
©2007 by the McGraw-Hill Companies, Inc. All rights reserved. 2/e PPTPPT.
> a patent search service supplied by Patents & Technology Surveys Ltd PROFESSIONAL ONLINE PATENT INFORMATION SERVICE.
1 Chapter 6 Copyright ©2006 Thomson South-Western, Mason, Ohio William A. Raabe, Gerald E. Whittenburg, & Debra L. Sanders Tax Services and Periodicals.
Practice Management Training Webinar - Chapter 4 of 4 Ros Campbell Product Consultant.
Policy? Guidance? Standard Operating Procedure? Tips on how to achieve compliance with minimum red tape Carolyn Bargoot, Associate Director Post-Award.
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
MONITORING THE VALUE OF TRIAL REGISTER INFORMATION Thomson Pharmaceutical Services LAWRENCE LIBERTI MS, RPh, RAC JULY 16, 2008.
Practice Management Training Webinar - Chapter 3 of 4 Ros Campbell Product Consultant.
This presentation, including any supporting materials, is owned by Gartner, Inc. and/or its affiliates and is for the sole use of the intended Gartner.
Intellectual Property Rights (IPR) Helpdesk A presentation by Daniela Nolte.
What Works: for children with speech, language and communication needs? New database launched to help you find evidenced interventions appropriate for.
MODULE B: Case Report Forms Jane Fendl & Denise Thwing April 7, Version: Final 07-Apr-2010.
CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. REGULATORY INTELLIGENCE: INDUSTRY’S BEST PRACTICE OMICS 5 th International Pharmaceutical.
Author Instructions How to upload Abstracts and Sessions to the Paper Management System.
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.
Introduction to Drug Rediscovery John Lisman Attorney-at-law Lisman Legal Life sciences Insert your logo in this area then delete this text box.
How to audit the role of the vendor in the conduct of outsourced studies Kristel Van de Voorde Director Global Quality Regulatory Compliance Bristol-Myers.
Presenter Name Title Organization Twitter Handle Insert your logo here, then delete text.
RESEARCH PROPOSAL: HOW TO REVIEW THE LITERATURE MNGT Özge Can.
Click to add Presentation Title Arial 32, 5 line max title space line 3, title space line 4, title space line 5 Presenter Title Organization Insert your.
1 Optimal Strategies for Preparing Integrated and Clinical Summaries for a New Drug Application: Making it Work Under Any Circumstance Lisa A. Pierchala,
Virtual Business Virtual Communication Copyright © Texas Education Agency, All rights reserved.
Author Instructions How to upload Abstracts and Sessions to the Paper Management System.
Copyright © 2014 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
Author Instructions How to upload Abstracts and Sessions to the Paper Management System.
The Research Process Why Do Research? Tennessee State University Undergraduate Classes.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
Accurate  Consistent  Compliant Contact: i4i the structured content company the structured content company.
How to successfully Implement and Leverage the Regulatory Intelligence Function Marianne Koehne EU RI Network Group; Global RI Manager Boehringer Ingelheim.
Linda Bowen Regulatory Intelligence sanofi-aventis
Communicating Actionable Regulatory Intelligence João Duarte Regulatory Intelligence Strategy Leader H. Lundbeck A/S.
Making Comments Count for High-Impact Regulations and Guidelines in the US Virginia (Ginny) Beakes-Read Executive Director, Global Regulatory Policy and.
Strategic Analyses and Interpretation: Regulatory Intelligence for Decision Making Amy N. Grant Director, Regulatory Strategy & Science ViroPharma Incorporated.
Good Laboratory Practices and Inspection Readiness Paul Swidersky President/Sr. Consultant Quality Associates, Inc.
Draft White Paper “Protocol Deviations”
Experience sharing - Introducing a tool for announcing and tracking attendance at conferences and congresses Global Regulatory Policy – Regulatory Sciences:
DIA ERS SIAC IND CMC eCTD Submissions Part II – IND to NDA
Process-based Metadata From a DIA Presentation: eTMF – Migrating from Paper Trial Master Files to Electronic Eldin Rammell, Managing Director, Rammell.
Experiences from building a lessons- learned database for regulatory interactions Åsa Rembratt Sr Reg Intelligence Manager Novo Nordisk A/S 26th Annual.
Group Sequential Tests for Delayed Responses Christopher Jennison Department of Mathematical Sciences University of Bath Lisa Hampson Department of Mathematics.
Making Comments Count for High-Impact Regulations and Guidelines in Canada, EU, Japan, and US Chairperson: Amy N. Grant Director, Regulatory Strategy &
Gabor Fari Life Sciences Solution Strategist Microsoft Corporation
- A “Portable” Implementation
Mutagenic Impurities: Guidances Update w/ CMC Perspectives
Verizon Business Net Conferencing
Presenter Title Organization
Track 11 Symposium 27 June :30 – 3:00 PM
Perspective on GCP Warning Letters
Do You Copy That? A Presentation about Copyright
Molly Butler Auditor II Quality Associates, Inc.
Interactive Session: Presentation of Scenarios and Q&A
Community-Based and Cluster-Randomized Studies –‘Pragmatic’ Approaches for Life Cycle Evidence? Florian Eichmann, PhD Principal Scientific Affairs and.
FirstPoint and FirstDoc Application of the DIA EDM Reference Model
Presenter Name Title Organization.
1 Topic Title First slide 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
GMP Inspection Process
Presenter Name Title Organization.
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.
1 Session Title 2 line 3 line 4 line
Research funding application process
1 Session Title 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
William W. Gregory for the CIOMS MLG Exploratory Team Pfizer Inc
MANUSCRIPT WRITING TIPS, TRICKS, & INFORMATION Madison Hedrick, MA
Presentation transcript:

Meredith Brown-Tuttle, RAC Director APT Pharmaceuticals, Inc. The Tools of Regulatory Intelligence: Where to Start when Developing Regulatory Strategy or Answering a Question Meredith Brown-Tuttle, RAC Director APT Pharmaceuticals, Inc.

Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated.   These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.

What is Regulatory Intelligence “The act of gathering and analyzing publicly available regulatory information. This includes communicating the implications of that information, and monitoring the current regulatory environment for opportunities to shape future regulations, guidance, policy, and legislation.” DIA Regulatory SIAC, Regulatory Intelligence Working Group Copyright 2009 Meredith Brown-Tuttle

What is Regulatory Information? Can be oral, written, published, unpublished, etc. Basic building blocks of intelligence, the raw information Copyright 2009 Meredith Brown-Tuttle

Information vs. Intelligence Intelligence is active and related to analysis and surveillance Information is the raw data used to create intelligence Copyright 2009 Meredith Brown-Tuttle

Regulatory Intelligence RI allows a regulatory professional to Create a strategy for a product Create a development plan for product Research past precedence and adjust for current regulatory climate Advise personnel Write or construct a marketing application incorporating all Agency requirements and Adjust marketing application to ROW needs Copyright 2009 Meredith Brown-Tuttle

Copyright 2009 Meredith Brown-Tuttle Researching the Topic Define your topic with key words or concepts such as: transdermal patch validation batch 505(b)(2) done to date for analgesics How to file a 505(b)(2) How to file Canadian CTA, INN Name, etc. How many products received fast track, priority review and received orphan designation Don’t be afraid to use Google! Copyright 2009 Meredith Brown-Tuttle

Copyright 2009 Meredith Brown-Tuttle Researching the Topic Use key terms as you would for a Medline search If subject looking for is complex, break it down into a few key words to start with Can do a “search within results” to further refine topic if too many “hits” are returned or if need to add more key words Be willing to put the time in to drill down into documents Do a search for terms on screen (control f) Copyright 2009 Meredith Brown-Tuttle

Copyright 2009 Meredith Brown-Tuttle Researching the Topic Develop checklists for where to start for certain questions Checklists are divided by clinical, nonclinical and CMC Checklists give sources to start with so you make sure you check all available sources Great to have on hand for training Copyright 2009 Meredith Brown-Tuttle

Sources of Regulatory Intelligence Common: Regulations Guidance Documents (preamble and comments) Panel Meetings Previous approvals Less common Interactions with reviewers Warning Letters/Untitled Letters Interactions with other regulatory professionals FDA presentations Competitor information FOI requests Compliance guides MAPPs Copyright 2009 Meredith Brown-Tuttle

More than Regulations and Guidance Documents Regulations and guidance documents tell ½ the story. These sources describe the black and white story … most of regulatory is gray! Guidance may be waived There might be no guidance at all Interpretation of guidance varies with company and their experience Copyright 2009 Meredith Brown-Tuttle

Regulatory Information Finding regulatory information is not usually found in one location. You need to have numerous sleuthing techniques in your armamentarium to be able to address the scope and breadth of questions posed to you For each question put forth, there are numerous sources to begin your search Copyright 2009 Meredith Brown-Tuttle

Sources of Regulatory Information On-line professional and scientific article subscriptions Regulatory agency Web sites Previous regulatory submissions (internal to the company) Competitor’s previous submissions Competitor’s marketing literature Specialized regulatory intelligence software Copyright 2009 Meredith Brown-Tuttle

Sources of Regulatory Information Email alerts Educational conferences Regulatory reference and information sites Local chapter meetings of various organizations. Colleagues Business intelligence websites and databases FDA Advisory Committee meeting minutes Books Consultants Copyright 2009 Meredith Brown-Tuttle

Regulatory Information Databases Provide the ability to conduct focused research and surveillance, some summarizing and integration Provide daily or weekly updates Some provide limited analysis of documents Still need to do analysis of information and impact to current program/product Allow for integration of regulations into SOPs Copyright 2009 Meredith Brown-Tuttle

Regulatory Information Databases 80+ countries available out of 194 in the world Country specific regulations provided in the local language (can translate for a fee) Key word or full text searches by country of choice Information structured logically by subject matter Access to current, revoked and draft documentation/information Expert summaries/Explanatory documents Copyright 2009 Meredith Brown-Tuttle

Regulatory Information Databases Explanatory documents that guide you through a country’s drug/device registration process How to start a clinical trial Maintenance of a clinical trial Adverse Event Reporting Scientific Advice Orphan application How to construct a marketing application How to deal with variations or changes of marketed products Copyright 2009 Meredith Brown-Tuttle

Transforming Information into Intelligence Research topic and cull all pertinent information about your research topic from resources Read pertinent information about the research topic Write a summary of each piece of information once read Pull together all pieces of information and analyze how they fit and impact each other Write up your analysis Copyright 2009 Meredith Brown-Tuttle

Transforming Information into Intelligence Once you have summarized the information, you will need to put it in a standard format to integrate the current position and recent information to deliver information to your target audience Target audience can be: Regulatory department Product team General distribution to company as a whole Management Various departments Copyright 2009 Meredith Brown-Tuttle

Transforming Information into Intelligence Subject: CMC, Clinical, Safety, non-clinical, etc. Regulations, directives, guidance documents… Proposed or recently codified regulation/ directive/guidance document Explanation of how recent information will affect current practice and proposed changes (if any) to current practices to comply or be in-line with new information How will new information affect your target audience/team or strategy Save/file for future use and don’t be afraid to update Copyright 2009 Meredith Brown-Tuttle

Questions Contact Information askmeredith@usa.net 21